BioSpace News Archive

Silence Therapeutics plc today announced that the Company will present at the 21st Annual Needham Virtual Healthcare Conference at 8:00 a.m. Eastern Time on Thursday, April 14, 2022.

STAAR Surgical Company today announced the first implants of the EVO Visian® Implantable Collamer® lens (EVO ICL) in the U.S.

Alumis today announced the appointments of Sara Klein as general counsel and secretary and John R. Schroer as chief financial officer.

Bold Therapeutics, a clinical-stage biopharmaceutical company, announced that will be presenting research supporting the use of BOLD-100 in combination with a wide range of anticancer therapies in the treatment of numerous cancer types at the AACR Annual Meeting 2022 on April 8-13, 2022 in New Orleans.

Revelation Biosciences Inc. today announced that it will host investor conference call on April 7, 2022 at 4:30 p.m. Eastern Time.

Progenity, Inc. today announced the acceptance of two abstracts presenting preclinical data on its systemic therapeutics delivery system for presentation at the Controlled Release Society (CRS) 2022 Annual Meeting.

AffyImmune Therapeutics, Inc. announced today that it will present an abstract in a poster session at the 2022 American Association for Cancer Research (AACR) Annual Meeting.

Linnaeus Therapeutics, Inc. (“Linnaeus”), a privately held biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced it has been awarded a Phase 2 Bridge Small Business Innovation Research (“SBIR”) Award by the National Cancer Institute (“NCI”) of the National Institutes of Health (“NIH”).

BiOneCure Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared the IND for BIO-106, an antibody-drug conjugate (ADC) designed to target TROP-2 to treat a broad range of advanced solid tumors.

A premier, target-first and rational molecular glue discovery platform to identify preferred E3 ligases for priority disease targets Series A will fund activities to identify multiple, rationally designed molecular glue clinical candidates Dr. Patrick Trojer joined as President & CEO & Board Director TRIANA Biomedicines, Inc. announced their launch with $110 million in total funding to establish a best-in-class, scalable platform to discover and develop “molecular glues”.